Genetics & Environmental Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics & Environmental Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biopharmaceuticals
AVI BioPharma to Present on NEUGENE Countermeasures to Biological Threats at U.S. Department of Defense 2007 Biodefense Research Conference
November 22nd, 2007
AVI BioPharma, Inc. (NASDAQ:AVII), announced that Patrick L. Iversen, Ph.D., AVI's senior vice president of research and development, will present today at the inaugural 2007 Biodefense Research Conference, Bridging the Gap: Biodefense and Beyond, held Nov. 5-7 in Philadelphia. Dr. Iversen's presentation will include updates on studies performed at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) evaluating the company's NEUGENE(R) PLUS therapeutic antisense compounds in the treatment of nonhuman primates (NHP) exposed to Ebola virus or Marburg virus. In an Ebola follow-on study, two surviving NHP from a previous NEUGENE PLUS study were exposed...
Source: Genetics & Environmental Business Week (2007-11-22)
|
